Patents by Inventor Daniel C. St. Louis

Daniel C. St. Louis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for downregulating CCR5 in T cells with anti-CD3 antibodies and anti-CD28 antibodies
    Patent number: 7927595
    Abstract: Methods for modulating HIV-1 fusion cofactor expression by manipulating an accessory molecule on the surface of T cells, such as CD28, are described. The invention encompasses methods for modulating HIV-1 fusion cofactor expression by stimulating or inhibiting one or more intracellular signals which result from ligation of a surface receptor on a T cell which binds a costimulatory molecule. In one embodiment, expression of an HIV-1 fusion cofactor, such as CCR5, is downregulated by stimulating a CD28-associated signal in the T cell.
    Type: Grant
    Filed: February 20, 1998
    Date of Patent: April 19, 2011
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventors: Carl H. June, Richard G. Carroll, James L. Riley, Daniel C. St. Louis, Bruce L. Levine
  • Method for inhibiting human tumor cells
    Patent number: 6410326
    Abstract: Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 25, 2002
    Assignee: Chiron Corporation
    Inventors: Harry E. Gruber, Douglas J. Jolly, James G. Respess, Paul K. Laikind, Jack R. Barber, Daniel C. St. Louis, Sunil D. Chada, Stephen M. W. Chang, John F. Warner
  • Method for making reflection defective retroviral vectors for infecting human cells
    Patent number: 5856185
    Abstract: Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 5, 1999
    Assignee: Chiron Corporation
    Inventors: Harry E. Gruber, Douglas J. Jolly, James G. Respess, Paul K. Laikind, Jack R. Barber, Daniel C. St. Louis, Sunil D. Chada, Stephen M. W. Chang, John F. Warner